Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir

The introduction of the so-called highly active antiretroviral therapies has had an impact on the natural history of the HIV infection

J.M Eiros Bouza; M Ortega; R.Ortiz de Lejarazu; R Blanco; P Bachiller; D.A de Luis

2004

Scholarcy highlights

  • The introduction of the so-called highly active antiretroviral therapies has had an impact on the natural history of the HIV infection
  • The aim of this contribution is to assess the differences in terms of plasma viral load, as a reflection of therapy success or failure
  • A retrospective study was made of the changes in VL in two cohorts of patients depending on the drugs included in the triple therapy prescribed to them
  • The comparison of the triple therapies containing any reverse transcriptase inhibitor and different protease inhibitors, indinavir versus saquinavir or ritonavir, showed a significantly higher percentage of patients reaching a ‘non-detectable’ VL among those receiving indinavir
  • The interval before VL levels rose above 30,000 RNA copies/ml was different in the two groups: 385 days for therapies including indinavir, and 239 days for saquinavir or ritonavir
  • This seems to support the excellent behaviour of indinavir when its efficiency is compared with other protease inhibitors acting as potential competitors

Need more features? Save interactive summary cards to your Scholarcy Library.